<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02966457</url>
  </required_header>
  <id_info>
    <org_study_id>HEM-3_1</org_study_id>
    <nct_id>NCT02966457</nct_id>
  </id_info>
  <brief_title>A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM)</brief_title>
  <acronym>DEHAM</acronym>
  <official_title>A Randomized Clinical Study of the Decolonization of MDR Gram-negative Bacteria in Patients With Haematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minsk State Clinical Hospital No 9</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Belarusian state medical university</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Minsk State Clinical Hospital No 9</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MDR (multidrug resistant) gram-negative bacteria have emerged as an important cause of
      bloodstream infection in hospitalized patients, especially in immunocompromised hosts. It was
      previously shown, that intestinal colonization with extended-spectrum β-lactamases
      (ESBL)-producing or carbapenem-resistant Enterobacteriaceae, carbapenem-resistant A.
      baumannii and P. aeruginosa) is a clinical predictor of bloodstream infections in patients
      with haematological malignancies and/or haematopoietic stem cell transplantation [Stoma I. et
      al., 2016].

      To the investigators knowledge no randomized, placebo-controlled clinical trial has been
      performed to study the efficacy and safety of selective intestinal decolonization strategies
      in high-risk patients with haematological malignancies. Possible decolonization of MDR
      gram-negative bacteria in haematological patients could be important for the patient by
      reducing the risk of infection and for the community by reducing the risk of transmission.

      The purpose of the proposed study is to assess the efficacy and safety of selective
      intestinal decolonization of MDR gram-negative bacteria with oral administration of
      Colistimethate sodium in high risk patients with haematological malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of eradication of ESBL-producing or carbapenem-resistant Enterobacteriaceae, carbapenem-resistant A. baumannii or P. aeruginosa at day 21 post-treatment</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of resistance of isolated on day 21 post-treatment Enterobacteriaceae, A. baumannii, P. aeruginosa to polymyxin antibiotics</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Hematological Infection</condition>
  <arm_group>
    <arm_group_label>Selective intestinal decolonization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Decolonization with Colistimethate sodium (2 mln I.U. 4x/day PO) for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Wait and watch&quot; strategy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group without decolonization interventions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colistimethate Sodium</intervention_name>
    <description>Selective oral intestinal decolonization</description>
    <arm_group_label>Selective intestinal decolonization</arm_group_label>
    <other_name>Colistin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Microbiologically proven rectal carriage of ESBL-producing Enterobacteriaceae or
             carbapenem-resistant Enterobacteriaceae, A. baumannii, P. aeruginosa without signs and
             symptoms of active infection.

          2. Patient must give written informed consent to participate in the study. The informed
             consent can be given by the legal representative if necessary.

        Exclusion Criteria:

          1. Active bacterial, viral, fungal or protozoal infection

          2. Women who are pregnant or nursing

          3. Antibacterial therapy in previous 10 days

          4. Contraindication to the use of one of the study drugs (including known
             hypersensitivity)

          5. Patient already enrolled in another study, or in the present study for a previous
             episode

          6. Psychiatric disorder or unable to understand or to follow the protocol directions

          7. Resistance of the primarily isolated colonizing microorganism to polymyxin antibiotics
             proven by methods of polymerase chain reaction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ihar Iskrou, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Republican Center of Hematology and Bone Marrow Transplantation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Republican Center of Hematology and Bone Marrow Transplantation</name>
      <address>
        <city>Minsk</city>
        <zip>220045</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
  </location_countries>
  <reference>
    <citation>Stoma I, Karpov I, Milanovich N, Uss A, Iskrov I. Risk factors for mortality in patients with bloodstream infections during the pre-engraftment period after hematopoietic stem cell transplantation. Blood Res. 2016 Jun;51(2):102-6. doi: 10.5045/br.2016.51.2.102. Epub 2016 Jun 23.</citation>
    <PMID>27382554</PMID>
  </reference>
  <reference>
    <citation>Rieg S, Küpper MF, de With K, Serr A, Bohnert JA, Kern WV. Intestinal decolonization of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBL): a retrospective observational study in patients at risk for infection and a brief review of the literature. BMC Infect Dis. 2015 Oct 28;15:475. doi: 10.1186/s12879-015-1225-0.</citation>
    <PMID>26511929</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2016</study_first_submitted>
  <study_first_submitted_qc>November 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2016</study_first_posted>
  <last_update_submitted>December 26, 2017</last_update_submitted>
  <last_update_submitted_qc>December 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Minsk State Clinical Hospital No 9</investigator_affiliation>
    <investigator_full_name>Ihar Iskrou</investigator_full_name>
    <investigator_title>Head of Cell Transplant Division</investigator_title>
  </responsible_party>
  <keyword>hematological infection, decolonization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colistin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>January 8, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

